Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Down 58.7% in July

Universe Pharmaceuticals INC (NASDAQ:UPC) was the recipient of a significant drop in short interest in July. As of July 31st, there was short interest totaling 6,382 shares, a drop of 58.7% from the July 15th total of 15,446 shares. Based on an average daily trading volume, of 1,046,971 shares, the short-interest ratio is presently 0.0 days. Currently, 0.3% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Universe Pharmaceuticals Stock Performance

UPC stock opened at $5.65 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.90 and a current ratio of 4.05. Universe Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $17.96. The stock’s 50 day moving average is $4.66 and its 200-day moving average is $3.60.

Universe Pharmaceuticals (NASDAQ:UPC) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($1.38) earnings per share (EPS) for the quarter. The company had revenue of $4.52 million during the quarter.

Universe Pharmaceuticals Company Profile

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.